A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TCC1727 Tablets in Patients With Advanced Solid Tumor
Latest Information Update: 25 Mar 2025
At a glance
- Drugs TCC 1727 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Beijing Tide Pharmaceutical
Most Recent Events
- 18 Mar 2025 Planned End Date changed from 30 Sep 2025 to 30 Dec 2025.
- 18 Mar 2025 Planned primary completion date changed from 30 Mar 2025 to 30 Jul 2025.
- 15 Dec 2023 Status changed from not yet recruiting to recruiting.